I look into why Wegovy possibly got approved at a 2.4mg dosage. What were the percentage of side effects found in clinical trials and why the hell did our Government Regulators say "yes". We take a look at the speed of weight loss and why it matters in Advertising. Plus what GLP1's have in common with the smash hit show "The Biggest Loser". I push for more personalised dosages of semaglutide and we look at the battle of Big Pharma for the consumer dollar and how it all comes down to being the ultimate biggest loser.... because who the hell remembers the runner up?
Contact
investigatingozempic@gmail.com
Special Note
In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.
Legal and Medical Disclaimer:
The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.
Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.
Copyright
All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.
Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.
LINKS TO DOCUMENTS MENTIONED
Wegovy Dosage Trial
Ozempic Dosage Trial
2019 Review of GLP1 by 20 Scientists
STEP 1 Clinical Trial
STEP 2 Clinical Trial
STEP 3 Clinical Trial
STEP 4 Clinical Trial
STEP 5 Clinical Trial
Adolescent STEP Clinical Trial
Tirzepeptide vs Semaglutide
https://pubmed.ncbi.nlm.nih.gov/37344384/
Lower Cagrisema Media Notice
Blue Health Intelligence Survey
